AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares were seen trading lower by $10.50 at $25.20 in Monday's session.
Before the open, the issue company issued FY 2017 sales that surrounded current estimates. Also, the company announced an exclusive
licensing agreement with Palatin Technologies, Inc. (NYSE: PTN) for North American rights to Rekyndatm.
However, that news has been overshadowed by a downgrade at Raymond James. The analysts changed their rating from Market Perform
to Underperform. Its $4.00 plus lower opening price of $31.55 has turned out to be the high for the session.
The ensuing decline has taken the issue to $23.90, but it has rebounded back into the $25.00 handle. That low coincides with a
pair of lows from November 3 and 4 at $23.80.
Latest Ratings for AMAG
| Date |
Firm |
Action |
From |
To |
| Jan 2017 |
Raymond James |
Downgrades |
Market Perform |
Underperform |
| Jan 2017 |
Janney Capital |
Initiates Coverage On |
|
Buy |
| Dec 2016 |
Cantor Fitzgerald |
Initiates Coverage On |
|
Neutral |
View More Analyst Ratings for
AMAG
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.